Search Results - anthrax

19 Results Sort By:
Expression, Purification, and Validation of Anthrax Toxin Proteins
Expression, purification, and validation of anthrax toxin proteins.
Published: 10/28/2024   |   Inventor(s): Rasem Fattah, Stephen Leppla
Keywords(s): Anthrax, Expression, proteins, purification, RM, toxin, Validation, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials
Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor
Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA. Protective antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla
Keywords(s): Acid, AMINO, Anthrax, ANTIGEN, Edema, factor, Lethal, Listed LPM Ano as of 4/15/2015, Mutants, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, RM, SUBSTITUTIONS, VJXXXX, WIXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials
Plasmids Encoding and Producing Anthrax Toxin Proteins
Plasmid pSJ136-EF-A — A plasmid encoding mutant anthrax toxin proteins such as lethal factor (LF) or edema factor (EF). Anthrax toxin and anthrax toxin fusion proteins may be used as therapeutic agents for cancer. Plasmid PSJ115-LFOS — A plasmid expressing anthrax toxin proteins such as lethal factor (LF) or edema factor (EF) which has the original...
Published: 10/28/2024   |   Inventor(s): Pradeep Gupta, Yiu Cheung, Haijing Hu, Mahtab Moayeri, Stephen Leppla
Keywords(s): Anthrax, Improved, Listed LPM Soukas as of 4/15/2015, Methods, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, proteins, RM, TOXINS, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu
Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration
Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin
This CDC developed invention identifies an assay for extremely fast and sensitive detection of Bacillus anthracis lethal toxin (LTx), the toxin responsible for the lethal effects of anthrax infection. This assay has already been successfully tested in animals and will allow for early detection of anthrax exposure and screening of lethal factors to...
Published: 10/28/2024   |   Inventor(s): Conrad Quinn, John Barr, Anne Boyer
Keywords(s): 02706, AA5XXX, AAXXXX, Anthrax, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, Detection, Diagnosis, diagnostic, Diagnostic assay, diagnostic in vitro, DXXXXX, FACTORS, I01306, I-013-06, I-027-06, ONDIEH-NCEH, Pathogenicity, VBXXXX, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX, YDXXXX, YEXXXX
Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Consumer Products, ResearchProducts > Antibodies, Application > Research Materials, Application > Occupational Safety and Health, Application > Diagnostics
Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics
CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax...
Published: 10/28/2024   |   Inventor(s): Dennis Bagarozzi, Anne Boyer, Conrad Quinn, Jason Goldstein
Keywords(s): Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic
Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, ResearchProducts > Antibodies, Application > Diagnostics
Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection...
Published: 10/28/2024   |   Inventor(s): Conrad Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad Schiffer, Stephen Soroka, Vera Semenova
Keywords(s): Anthrax, ANTIGEN, Bacillus, biosecurity, Bioterrism, Bio-terrorism, Bioterrorist, BioWarfare, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC1XXX, DC4XXX, DCXXXX, Development, DXXXXX, Epitopes, LINEAR, OID-NCIRD-DBD, PA, Peptide, Protection, Protective, toxin, Vaccine
Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Christopher Bachran, Stephen Leppla
Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics
Engineered Anthrax Toxin Variants that Target Cancer
This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath
Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath
Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases
1 2